Vol. 5 No. 12 (2025)
Reimbursement Reviews

Quizartinib (Vanflyta)

decorative image of the issue cover

Published December 24, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses quizartinib (Vanflyta), 17.7 mg or 26.5 mg tablets, oral.
  • Indication: In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib maintenance monotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 internal tandem duplication positive.